From Trial to Trial: Diminishing Effects Sizes of Interventions for Myopia Control – a Call for Critical Reassessment

Myopia and the reduction of its progression in children and adolescents is an exciting area of research, with promising developments as well as numerous unanswered questions. This issue of Klinische Monatsblätter für Augenheilkunde addresses the multifaceted challenge of myopia featuring a series of English-language articles covering myopia epidemiology, retinal complications of high myopia, pharmacologic treatment with atropine, optical inventions, and chromatic light therapy. My thanks go to all authors for their support, enthusiasm, and time invested in this special issue!

Publikationsverlauf

Artikel online veröffentlicht:
09. Oktober 2024

• References

• 1 Dolgin E. The myopia boom. Nature 2015; 519: 276-278
• 2 Chia A, Chua WH, Cheung YB. et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5 %, 0.1 %, and 0.01 % doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012; 119: 347-354
• 3 Schuster AK, Elflein HM, Pokora R. et al. [Prevalence and Risk Factors of Myopia in Children and Adolescents in Germany – Results of the KiGGS Survey]. Klin Padiatr 2017; 229: 234-240
• 4 Schuster AK, Krause L, Kuchenbäcker C. et al. Prevalence and Time Trends in Myopia Among Children and Adolescents. Dtsch Arzteblatt Int 2020; 117: 855-860
• 5 Wesemann W. [Analysis of spectacle lens prescriptions shows no increase of myopia in Germany from 2000 to 2015]. Ophthalmologe 2018; 115: 409-417
• 6 Williams KM, Verhoeven VJM, Cumberland P. et al. Prevalence of refractive error in Europe: the European Eye Epidemiology (E(3)) Consortium. Eur J Epidemiol 2015; 30: 305-315
• 7 Tideman JWL, Snabel MCC, Tedja MS. et al. Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. JAMA Ophthalmol 2016; 134: 1355-1363
• 8 Loughman J, Kobia-Acquah E, Lingham G. et al. Myopia outcome study of atropine in children: Two-year result of daily 0.01 % atropine in a European population. Acta Ophthalmol 2024; 102: e245-e256
• 9 Zadnik K, Schulman E, Flitcroft I. et al. Efficacy and Safety of 0.01 % and 0.02 % Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol 2023; 141: 990-999